GHR and non-small cell lung carcinoma: Given that pharmacologic inhibition of GHR with pegvisomant effectively mitigated these pro-tumorigenic effects, additional inhibitors of GH action potentially qualify as strategies to enhance chemotherapy efficacy and limit tumor progression in NSCLC.